ClinicalTrialsFinder
RecruitingEarly Phase 1NCT07767630

Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma

An Exploratory Proof-of-Concept (POC) Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Fractionated Dosing of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma (Including a Run-in Phase)

Sponsor

Sichuan University

Enrollment

10 participants

Start Date

Jul 21, 2026

Study Type

INTERVENTIONAL

Conditions

Neuroblastoma (NB)

Summary

Fractionated dosing of \[211At\]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma

Eligibility

Min Age: 1 YearMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called [211At]MABG for people with neuroblastoma (nb). The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Year to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[211At]MABG

Fractionated Dose

Locations(1)

West China Hospital

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07767630

Related Trials

Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children

NCT073188311 location

Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma

NCT073755631 location

Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma

NCT070647461 location

Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma

NCT066742651 location

Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.

NCT068365053 locations